Last updated: November 11, 2026
Elaprase, the commercial brand for idursulfase, is a long-established enzyme replacement therapy for Hunter syndrome, or mucopolysaccharidosis type II (MPS II). Takeda inherited the product through its acquisition of Shire in 2019. The product remains commercially durable because MPS II is ultra-rare, treatment is chronic, switching is clinically sensitive, and manufacturing recombinant lysosomal enzymes is difficult. Its main commercial constraints are high treatment cost, a restricted patient population, infusion burden, and limited expansion potential.
Takeda does not generally disclose Elaprase revenue as a standalone global product line in its current financial reporting. Earlier Shire filings reported annual sales in the low-to-mid hundreds of millions of U.S. dollars. Takeda’s subsequent reporting groups Elaprase within broader rare-disease or specialty portfolios, limiting precise year-by-year revenue reconstruction. [1-4]
What is Elaprase and which patients does it treat?
Elaprase is recombinant human iduronate-2-sulfatase, or idursulfase. It is administered by intravenous infusion at a recommended dose of 0.5 mg/kg every week. The product replaces deficient lysosomal enzyme activity in patients with Hunter syndrome. [5]
| Attribute |
Elaprase |
| Active ingredient |
Idursulfase |
| Therapeutic category |
Enzyme replacement therapy |
| Disease |
Mucopolysaccharidosis type II |
| Brand owner |
Takeda Pharmaceutical Company |
| Original developer |
Shire Human Genetic Therapies |
| FDA approval |
July 24, 2006 |
| FDA pathway |
Biologics license application |
| Administration |
Weekly intravenous infusion |
| U.S. orphan exclusivity |
Seven years from approval |
| Primary commercial market |
United States, Europe, Japan and other developed markets |
| Principal competitors |
Hunterase, gene-therapy programs and supportive care, rather than conventional small-molecule generics |
The product is indicated for patients with Hunter syndrome, a predominantly male X-linked disorder caused by mutations in the IDS gene. The disease produces progressive accumulation of glycosaminoglycans and can affect the skeleton, airways, cardiovascular system, hearing and other organs. [5]
The clinical value proposition is strongest in patients who begin treatment before irreversible disease progression. That supports continuing demand but also makes diagnosis, pediatric treatment initiation and long-term infusion access important commercial drivers.
When did Elaprase lose exclusivity?
Elaprase’s U.S. orphan-drug exclusivity expired in July 2013, seven years after FDA approval. Orphan exclusivity blocked FDA approval of the same drug for the same indication during that period, subject to statutory exceptions. It did not prevent all competing therapies or permanently block biologic competition. [5-7]
The principal U.S. composition-of-matter patent historically associated with idursulfase was U.S. Patent No. 5,580,757, covering recombinant human iduronate-2-sulfatase technology. The patent was filed before the current 20-year patent-term framework applied to most pharmaceutical patents and reached the end of its enforceable term well before the product’s current commercial life. [8]
Elaprase exclusivity timeline
| Date |
Event |
| 1990s |
Recombinant iduronate-2-sulfatase patent activity |
| July 24, 2006 |
FDA approves Elaprase |
| July 24, 2013 |
U.S. orphan-drug exclusivity expires |
| 2010s |
Core U.S. composition patent protection ends |
| 2019 |
Takeda completes acquisition of Shire |
| 2020s |
Product remains marketed without a conventional generic substitute |
The end of formal orphan and composition-patent exclusivity did not produce immediate market erosion. Elaprase is a complex biologic manufactured in mammalian cells, requiring controlled glycosylation, purification, potency testing and stability controls. Those requirements create a higher entry barrier than the expiry of the core patent would suggest.
What is the Orange Book status of Elaprase?
Elaprase is not an Orange Book product in the conventional small-molecule sense. The Orange Book primarily records approved drug products and patent or exclusivity information relevant to abbreviated new drug applications. Elaprase was approved as a biologics license product, so biosimilar competition is governed by the Public Health Service Act and the FDA’s Purple Book rather than by an ANDA and Paragraph IV certification. [6,9]
A competitor seeking approval as a biosimilar would generally use the section 351(k) pathway. The applicant would need to demonstrate biosimilarity to the reference product through analytical, functional, pharmacokinetic and, where required, clinical evidence. Interchangeability would require a separate showing under the applicable FDA standard.
Does Elaprase have Paragraph IV challenges?
A conventional Paragraph IV challenge is not the standard route for Elaprase because Paragraph IV certifications apply to patents listed for small-molecule products in the Orange Book. A biosimilar applicant would instead address reference-product exclusivity and patent disputes under the Biologics Price Competition and Innovation Act, including the statutory patent-exchange process commonly called the patent dance. [6,9]
Publicly visible Elaprase competition has not developed in the form of the broad ANDA litigation seen for oral drugs. The relevant risk is a future 351(k) biosimilar or a clinically differentiated therapy, not a traditional generic launch.
How strong is the Elaprase patent estate?
The current patent estate is weaker than the commercial barriers surrounding the product. Core patent protection has expired or aged substantially, while manufacturing know-how, regulatory history and clinical adoption remain meaningful defenses.
| Protection category |
Current commercial relevance |
| Core recombinant-enzyme patents |
Limited in the United States after expiry |
| Process patents |
Potentially relevant if they cover commercially necessary production steps |
| Formulation patents |
May protect stability or presentation but are unlikely to block all biosimilar development |
| Method-of-use patents |
Could cover selected patient populations or dosing approaches |
| Trade secrets |
High relevance for cell lines, fermentation, purification and release testing |
| Regulatory exclusivity |
Original U.S. orphan exclusivity expired |
| Manufacturing scale |
Significant barrier because enzyme replacement products require complex biologic production |
What formulations are protected by Elaprase patents?
Elaprase is supplied as a sterile intravenous solution in single-use vials. The commercial formulation and manufacturing process depend on protein stability, glycosylation control, removal of process impurities and preservation of biological activity. [5]
Publicly available regulatory materials do not establish that a currently enforceable U.S. formulation patent blocks biosimilar development. Any formulation protection would need to be assessed claim by claim, including patent term, prosecution history, terminal disclaimers, continuation practice and whether the claims cover the marketed presentation rather than an alternative formulation.
What manufacturing barriers affect Elaprase competition?
Manufacturing is the more important barrier than the expired core patent. A competing developer must reproduce or sufficiently match:
- Enzyme identity and amino-acid sequence
- Glycan distribution
- Specific activity and substrate conversion
- Aggregation and impurity profiles
- Host-cell protein and residual DNA controls
- Sterility and endotoxin specifications
- Long-term stability under shipping and storage conditions
- Clinical exposure and immunogenicity characteristics
For lysosomal enzymes, small changes in glycosylation can affect cellular uptake and tissue distribution. That raises the technical and regulatory burden for biosimilar development. The same issues make manufacturing deviations commercially material even after approval.
How has Elaprase revenue changed over time?
Shire reported Elaprase revenue in the approximate $400 million range in several years before the Takeda transaction. The product was one of Shire’s established rare-disease franchises, supported by recurring weekly treatment and a high annual cost per patient. [1-3]
Takeda’s post-acquisition reporting does not consistently provide a standalone Elaprase revenue series. The company has reported product-level performance for selected growth products while grouping mature products into broader categories. As a result, precise current revenue cannot be inferred from Takeda’s consolidated financial statements without company-specific segment disclosures or estimates.
Reported commercial trajectory
| Period |
Commercial position |
| 2006-2013 |
Protected growth phase under orphan exclusivity |
| 2014-2018 |
Mature rare-disease product with continued recurring demand |
| 2019 |
Shire acquisition transfers Elaprase to Takeda |
| 2020-2022 |
Stable mature-product economics, with portfolio and currency effects |
| 2023 onward |
Mature revenue contribution; limited disclosed standalone visibility |
Revenue is influenced by four variables:
- Patient prevalence and diagnosis.
- Treatment initiation and persistence.
- Reimbursement and government pricing.
- Foreign-exchange movement across the United States, Europe and Japan.
The patient population limits volume growth. Revenue expansion therefore depends more on retention, geographic access and pricing than on broad market penetration.
What is the annual treatment cost of Elaprase?
Elaprase has historically been among the highest-cost chronic enzyme replacement therapies. The annual drug cost depends on body weight, dosing frequency, payer discounts, site-of-care economics and country-specific pricing. A 0.5 mg/kg weekly regimen translates into 26 mg per year for a 50 kg patient before wastage and vial-size effects, but pediatric patients and heavier adolescents require different quantities. [5]
The economic burden extends beyond the vial price. Weekly infusions require healthcare personnel, infusion facilities, premedication in some patients, monitoring and caregiver time. These costs influence payer utilization management and encourage home-infusion or alternative delivery strategies where clinically and regulatorily appropriate.
Because Hunter syndrome is rare, the product can sustain a high price with limited unit volume. The trade-off is concentration risk: a small number of treatment discontinuations, deaths, delayed diagnoses or switches can materially affect annual sales.
Which companies are challenging Elaprase?
No conventional generic company has created broad market disruption. Competitive pressure comes from three groups:
Biosimilar developers
A biosimilar idursulfase could compete on price, contracting and infusion-provider access. The absence of a widely established U.S. biosimilar market for idursulfase limits the immediate threat, but technical feasibility has improved as regulatory experience with complex biologics expands.
Alternative enzyme replacement products
Hunterase, an idursulfase product developed by Green Cross, has been marketed in selected international markets. Its geographic availability and regulatory status differ by country. It is not a universal substitute for Elaprase across all major markets. [10]
Gene-therapy developers
Gene therapy aims to provide sustained IDS expression rather than weekly enzyme replacement. Programs such as RGX-121 have targeted Hunter syndrome, but development-stage assets carry clinical, regulatory and durability risks. A successful therapy could reduce the addressable market for chronic Elaprase treatment, particularly in newly diagnosed pediatric patients. [11]
What regulatory risks affect Elaprase?
The main regulatory risk is not loss of an existing FDA approval. It is the emergence of a competing product with a better treatment burden or a durable disease-modifying effect.
Relevant risks include:
- Approval of a 351(k) biosimilar.
- Gene-therapy approval for Hunter syndrome.
- New evidence that narrows or expands the clinically preferred treatment population.
- Safety signals involving infusion reactions or immunogenicity.
- Reimbursement restrictions tied to cost-effectiveness.
- Country-specific tendering that favors lower-priced alternatives.
Elaprase’s FDA label includes warnings for hypersensitivity and serious infusion-related reactions. These risks are managed through infusion monitoring and clinical protocols, but they remain relevant to patient persistence and site-of-care decisions. [5]
What patent litigation and settlements affect Elaprase?
There is no widely reported, market-defining U.S. Paragraph IV litigation campaign involving Elaprase comparable to the litigation histories of major small-molecule brands. The absence of such litigation reflects the product’s biologic regulatory pathway and the lack of a large conventional generic market.
Future biosimilar litigation would likely involve:
- Patent validity and infringement claims.
- Manufacturing-process patents.
- Formulation or stability claims.
- The BPCIA patent-exchange process.
- Launch timing after regulatory approval.
- Injunctive relief and damages.
No major public settlement has established a known U.S. biosimilar launch date for idursulfase.
How does Elaprase compare with competing MPS therapies?
| Product |
Active ingredient |
Disease |
Administration |
Competitive position |
| Elaprase |
Idursulfase |
MPS II |
Weekly IV infusion |
Established global reference product |
| Hunterase |
Idursulfase |
MPS II |
IV infusion |
Regional competitor in selected markets |
| Aldurazyme |
Laronidase |
MPS I |
Weekly IV infusion |
Different enzyme and disease |
| Naglazyme |
Galsulfase |
MPS VI |
Weekly IV infusion |
Different enzyme and disease |
| Vimizim |
Elosulfase alfa |
MPS IV A |
Weekly IV infusion |
Different enzyme and disease |
| Hunter syndrome gene therapies |
IDS-based approaches |
MPS II |
One-time or limited administration under investigation |
Potentially disruptive, but development risk remains |
Elaprase’s strongest competitive advantage is clinical familiarity and accumulated treatment experience. Its main weakness is the requirement for lifelong weekly infusions and the limited evidence that it reverses established skeletal or central nervous system disease.
What generic entry scenarios exist for Elaprase?
Scenario 1: No near-term U.S. biosimilar
This remains commercially plausible because of the small market, complex manufacturing and development costs. Takeda would continue to generate mature recurring revenue with limited direct price erosion.
Scenario 2: One approved biosimilar
A single biosimilar could initially target institutional accounts, government tenders and price-sensitive markets. Substitution would likely be gradual because automatic interchangeability rules for biologics differ from generic substitution rules.
Scenario 3: Multiple biosimilars
Several competitors could produce contracting pressure, lower net prices and greater payer control. The effect would depend on interchangeability, physician confidence, infusion-provider relationships and supply reliability.
Scenario 4: Gene-therapy displacement
A durable therapy could reduce new patient starts and gradually shrink the chronic enzyme replacement pool. Existing patients may continue Elaprase if gene therapy is unavailable, unsuitable or not durable.
What is the geographic coverage of Elaprase?
Elaprase has been marketed across major developed markets, including the United States, Europe and Japan, with country-specific approvals, reimbursement rules and pricing. Takeda’s global infrastructure supports distribution, but rare-disease access remains uneven. Diagnosis rates, specialist availability and national reimbursement decisions determine effective market penetration more than patent coverage alone.
The commercial estate is strongest where:
- Hunter syndrome diagnosis is established.
- Specialty infusion centers are available.
- Orphan-drug reimbursement supports high-cost therapy.
- National procurement does not impose aggressive price reductions.
Emerging markets may provide patient access opportunities but generally contribute less revenue per patient because of reimbursement constraints and lower treatment penetration.
What is the investment outlook for Elaprase?
Elaprase is best classified as a mature, cash-generative rare-disease biologic rather than a growth asset. Its revenue profile has defensive characteristics:
- Chronic weekly dosing.
- Few approved alternatives.
- High switching friction.
- Specialist prescribing.
- Long treatment duration.
The key erosion risks are strategic rather than patent-driven. A biosimilar could reduce price, while gene therapy could reduce patient volume. Revenue concentration, currency volatility and limited diagnosis expansion constrain upside.
Takeda’s financial exposure is meaningful but not comparable with its largest growth products. Elaprase is unlikely to be a primary driver of group-level growth, yet it can remain valuable as part of a diversified rare-disease portfolio with established reimbursement and manufacturing infrastructure.
Key Takeaways
- Elaprase is idursulfase, an enzyme replacement therapy for Hunter syndrome.
- FDA approval occurred on July 24, 2006; U.S. orphan exclusivity expired in July 2013.
- The core U.S. patent estate is no longer the principal commercial barrier.
- Elaprase is regulated as a biologic, so biosimilar risk is more relevant than Paragraph IV generic risk.
- Takeda inherited the product through its 2019 acquisition of Shire.
- Historical Shire revenue was approximately $400 million annually in several pre-acquisition years.
- Current standalone Elaprase revenue is not consistently disclosed by Takeda.
- Manufacturing complexity, glycosylation control and small patient numbers slow biosimilar entry.
- Hunterase is a regional idursulfase competitor, while gene-therapy programs represent the larger long-term threat.
- The product’s financial profile is mature and resilient, with downside risk from biosimilars, gene therapy and payer pressure.
Frequently Asked Questions
Is Elaprase still patent protected?
Core U.S. composition-patent protection associated with idursulfase has expired. Remaining process, formulation or method-of-use claims must be reviewed individually and are not equivalent to broad composition-of-matter exclusivity.
Can a generic version of Elaprase be approved through an ANDA?
No. Elaprase is a biologic. A competing product would generally use the FDA’s 351(k) biosimilar pathway rather than the ANDA pathway used for conventional generics.
Is Elaprase interchangeable with a future idursulfase biosimilar?
Not automatically. Interchangeability would depend on FDA designation and applicable pharmacy-substitution rules. Biosimilarity alone does not create automatic substitution in the same way as a conventional generic.
Does Elaprase treat the neurological symptoms of Hunter syndrome?
Systemic enzyme replacement can address some somatic disease manifestations, but intravenous idursulfase has limited penetration across the blood-brain barrier. Neurological benefit is therefore a major limitation of the therapy. [5]
What would most reduce Elaprase sales?
A durable gene therapy with demonstrated clinical benefit would pose the largest long-term volume risk. A lower-priced biosimilar would create earlier price and contracting pressure but would likely erode sales more gradually.
References
- Shire plc. (2016). Annual report and accounts 2016.
- Shire plc. (2017). Annual report and accounts 2017.
- Shire plc. (2018). Annual report and accounts 2018.
- Takeda Pharmaceutical Company Limited. (2024). Annual report 2024.
- U.S. Food and Drug Administration. (2023). Elaprase (idursulfase) prescribing information.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity.
- U.S. Patent No. 5,580,757. (1996). Human iduronate-2-sulfatase.
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products.
- GC Pharma. (2024). Hunterase product information.
- Regenxbio Inc. (2024). Corporate and clinical development disclosures for RGX-121.
